Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terlipressin for Acute Kidney Injury in Liver Transplantation
NCT02059460Phase 4Completed
- Sponsor
- National Liver Institute
- Start
- May 2013
- Primary completion
- Dec 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of terlipressin in acute kidney injury (AKI) (2 arms), sponsored by National Liver Institute. Primary endpoint: Development of acute kidney injury at 5 days. Started May 2013; status: completed.
02
Drugs
terlipressin
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT02059460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059460.